このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era

A Prospective Cohort Study of Radiotherapy Target Volume Delineation Patterns in Locally Advanced Esophageal Cancer in the Immunotherapy Era

This prospective observational cohort study will evaluate different radiotherapy target volume delineation patterns in patients with locally advanced esophageal squamous cell carcinoma receiving radiotherapy combined with immunotherapy.

In routine clinical practice, physicians may use different margins around the primary tumor and different approaches to regional lymph node irradiation. The study will not assign participants to a specific radiotherapy strategy. Instead, participants will receive treatment according to routine clinical practice, and the actual radiotherapy plans will be recorded and analyzed.

The study will compare locoregional tumor control, recurrence patterns, survival, treatment-related toxicity, lymphocyte reduction, and completion of immunotherapy among patients receiving different target volume strategies. The main objective is to evaluate 2-year locoregional recurrence-free survival and to identify radiotherapy approaches that may achieve effective tumor control while reducing unnecessary radiation exposure and treatment-related toxicity.

調査の概要

詳細な説明

This is a prospective, non-interventional observational cohort study of patients with locally advanced esophageal squamous cell carcinoma treated with radiotherapy in combination with immunotherapy in routine clinical practice. Treatment decisions, including radiotherapy target volume delineation and systemic therapy, will be made by the treating physicians according to the patient's clinical condition and routine clinical practice and will not be assigned by the study protocol.

Eligible participants will be prospectively followed, and clinical, imaging, pathological, radiotherapy planning, systemic treatment, laboratory, toxicity, and follow-up data will be collected. Participants will be classified according to the radiotherapy strategy actually received, particularly the longitudinal gross tumor volume-to-clinical target volume (GTV-CTV) margin and the extent of regional lymph node irradiation, including involved-field irradiation and approaches incorporating partial elective nodal irradiation.

The primary objective is to compare 2-year locoregional recurrence-free survival among patients receiving different target volume delineation strategies. Additional outcomes include marginal and regional recurrence patterns, overall survival, treatment-related toxicity, lymphocyte reduction, immunotherapy completion, and other treatment outcomes.

The study will also evaluate whether clinical and biological factors, including tumor location and length, T and N stage, lymph node burden, PET/CT metabolic parameters, PD-L1 combined positive score, circulating tumor DNA status, and radiotherapy dosimetric parameters, are associated with the effectiveness and safety of different target volume strategies. Target trial emulation, propensity score methods, and multivariable models will be used where appropriate to reduce confounding and to explore factors associated with recurrence and toxicity.

研究の種類

観察的

入学 (推定)

500

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100021
        • 募集
        • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients with locally advanced esophageal squamous cell carcinoma who are treated at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College and are considered suitable for definitive or preoperative radiotherapy combined with immunotherapy will be prospectively and consecutively enrolled. Treatment decisions will be made according to routine clinical practice. Participants will be followed to evaluate the association between actual radiotherapy target volume delineation patterns and locoregional control, recurrence, survival, toxicity, lymphocyte reduction, and immunotherapy completion.

説明

Inclusion Criteria:

  1. Age 18 to 80 years, regardless of sex.
  2. Histologically confirmed esophageal squamous cell carcinoma.
  3. Clinical stage cT2-4aN0-3M0, or considered by a multidisciplinary team to be suitable for definitive immunotherapy combined with radiotherapy or preoperative immunotherapy combined with radiotherapy.
  4. Planned to receive one of the following modern precision radiotherapy techniques: IMRT, VMAT, TOMO, proton therapy, or heavy-ion radiotherapy.
  5. Contrast-enhanced CT completed before radiotherapy; endoscopy, EUS, PET/CT, or MRI is recommended when clinically appropriate to assist target volume delineation.
  6. ECOG performance status of 0-2.
  7. Expected survival of at least 6 months.
  8. Able to understand the study and provide written informed consent.

Exclusion Criteria:

  1. Presence of distant metastasis or malignant pleural or peritoneal effusion.
  2. Previous thoracic radiotherapy that may affect the current target volume design or dose constraints.
  3. Pre-existing esophagotracheal fistula, esophagoaortic fistula, or a high risk of perforation considered unsuitable for radiotherapy.
  4. Active interstitial lung disease, severe infection, or uncontrolled autoimmune disease considered unsuitable for immunotherapy.
  5. Severe missing data that prevent determination of the actual CTV margin, lymph node irradiation extent, or major study outcomes.
  6. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Locally Advanced ESCC Cohort

Patients with locally advanced esophageal squamous cell carcinoma who receive radiotherapy combined with immunotherapy in routine clinical practice will be prospectively enrolled. Treatment and radiotherapy target volume delineation will not be assigned by the study protocol. Patients will be characterized according to the radiotherapy strategy actually received, including the longitudinal GTV-CTV margin and the extent of regional lymph node irradiation. Clinical, imaging, pathological, dosimetric, treatment, toxicity, and follow-up data will be prospectively collected to evaluate locoregional control, recurrence patterns, survival, lymphocyte reduction, and immunotherapy completion.

The longitudinal margin from the gross tumor volume (GTV) to the clinical target volume (CTV) actually used in routine clinical practice will be recorded and analyzed. The study protocol does not assign a specific margin.

The extent of regional lymph node irradiation actually used in routine clinical practice, including involved-field irradiation and approaches incorporating partial elective nodal irradiation, will be recorded and analyzed. The study protocol does not assign a specific nodal irradiation strategy.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
2-Year Locoregional Recurrence-Free Survival
時間枠:Up to 2 years from the start of radiotherapy

Locoregional recurrence-free survival (LRFS) is defined as the time from the start of radiotherapy to locoregional tumor recurrence, death from any cause, loss to follow-up, or the last follow-up, according to the study protocol. The 2-year LRFS rate will be compared among patients receiving different radiotherapy target volume delineation strategies.

Up to 2 years from the start of radiotherapy

二次結果の測定

結果測定
メジャーの説明
時間枠
2-Year Overall Survival
時間枠:Up to 2 years from radiotherapy

Overall survival (OS) is defined as the time from the start of radiotherapy to death from any cause, loss to follow-up, or the last follow-up. The 2-year overall survival rate will be evaluated among participants receiving different radiotherapy target volume strategies.

Up to 2 years from radiotherapy
Marginal and Regional Recurrence Rate
時間枠:Up to 2 years from radiotherapy

The proportion of participants who develop marginal recurrence or regional lymph node recurrence during follow-up. Recurrence will be determined by pathological or cytological confirmation when available, or by serial imaging showing a new or progressively enlarging lesion consistent with recurrence.

Up to 2 years from radiotherapy
Incidence of Grade 3 or Higher Treatment-Related Toxicity
時間枠:From treatment initiation through 2-year follow-up

The incidence of grade 3 or higher treatment-related adverse events will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Toxicities of interest include radiotherapy-related and systemic treatment-related adverse events.

From treatment initiation through 2-year follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年8月23日

一次修了 (推定)

2034年7月30日

研究の完了 (推定)

2036年8月31日

試験登録日

最初に提出

2026年9月29日

QC基準を満たした最初の提出物

2026年9月29日

最初の投稿 (実際)

2026年10月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be shared with external researchers because the current study protocol does not include a plan for external sharing of participant-level data. Study data will be stored with controlled access and will be available only to authorized study personnel. Study results will be reported in aggregate form to protect participant privacy and confidentiality.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する